Skip to main content
. 2021 Jan 20;13(3):4242–4257. doi: 10.18632/aging.202386

Figure 2.

Figure 2

Oxaliplatin inhibited tumor growth of OSCC and caused upregulation of PARP1 in vivo. (A) The xenograft models using BALB/c mice are shown. (B) The tumors derived from BALB/c mice are shown. (C) The volumes of tumors during the 21 days of treatment. (D) The average weight of tumors after treatment with oxaliplatin or PBS for 21 days. (E) Representative images of PARP1immunohistochemical staining of xenografts in control and oxaliplatin treatment group. (F) Relative mean optical density (MOD) of PARP1 in control and oxaliplatin treatment group. * p<0.05, **p<0.01.